Revenue
2013
2014
2015
2016
2017
2018
2019
Q/C TECHNOLOGIES, INC. (QCLS)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $1.6M | $1.7M | $3.4M | $3.0M | $2.1M | $4.4M | $3.6M |
| Gross profit | — | — | — | — | — | — | $478,747 | $127,285 | $948,580 | $1.9M | $1.2M | $3.3M | $1.7M |
| Research & development | $3.5M | $3.4M | $7.9M | $9.1M | $6.7M | $2.5M | $276,788 | $1.1M | $1.3M | $1.2M | $1.4M | $916,308 | $1.0M |
| Operating income | −$9.8M | −$10.2M | −$17.1M | −$15.3M | −$28.8M | −$9.5M | −$3.5M | −$10.1M | −$6.6M | −$3.3M | −$9.7M | −$3.2M | −$1.8M |
| EBITDAderived | — | — | — | — | — | −$9.5M | −$3.4M | −$9.8M | −$6.4M | −$3.0M | −$9.4M | −$2.9M | −$1.5M |
| Net income | −$11.6M | −$23.4M | −$4.0M | −$15.2M | −$29.9M | −$9.5M | −$3.9M | −$10.8M | −$7.4M | −$3.3M | −$9.3M | −$3.1M | −$1.5M |
| Basic EPSper diluted share | -$8.66 | -$1,080.87 | -$5.33 | -$11.74 | -$0.85 | -$2.49 | -$6.35 | -$22.28 | -$6.29 | -$0.61 | -$1.81 | -$0.66 | -$0.96 |
| Diluted EPSper diluted share | -$8.66 | -$1,080.87 | -$5.33 | -$11.74 | — | -$2.49 | -$6.35 | -$22.28 | -$6.29 | -$0.61 | -$1.81 | -$0.66 | -$0.96 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 30, 2026Form 4 | Voss Chelsea SierraDirector | BuyCommon stock · indirect | 1.8K | $3.15 | $5.5K | 61.6K |
| Nov 14, 2025Form 4 | PharmaCyte Biotech, Inc.TenPercentOwner | BuyWarrants · derivative | 889.9K | — | — | 889.9K |
| Sep 4, 2025Form 4 | PharmaCyte Biotech, Inc.TenPercentOwner | BuySeries H Convertible Preferred Stock · derivative | 889.9K | — | — | 889.9K |